 This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab MPDL3280A plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic renal cell carcinoma RCC who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting. 